Physician profile
Christopher James Smith
NPI 1053817981
$21,765.67
in general payments reported to CMS, 2019-2025
6 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,054 · 2024: $1,227 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $4,476 · Consulting Fee: $2,670 · Travel and Lodging: $2,063 · Long Term Medical Supply Or Device Loan: $27.72 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,510.00 |
| Food and Beverage | $4,476.37 |
| Consulting Fee | $2,670.00 |
| Travel and Lodging | $2,063.49 |
| Long Term Medical Supply Or Device Loan | $27.72 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20,828.91 | 2023-2025 | Biktarvy, Epclusa, Descovy |
| Viiv Healthcare Company | $651.77 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $148.62 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $83.03 | 2023 | |
| Baxter Healthcare | $27.72 | 2025 | Hillrom - Eli 280 |
| Stryker Corporation | $25.62 | 2023 | Simpliciti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.